ABSTRACT

CONCLUSIONS:

The ALCAPA syndrome should definitely be considered in th eetiology of cases diagnosed with dilated cardiomyopathy and it should be kept in mind that ALCAPA is completely treatable disease with early diagnosis and treatment.

RESULTS:

Of the 6 patients, 5 were female and 1 was male. The average age of diagnosis was 4,75 months. All patients had the signs and symptoms of heart failure at admission. All cases had the signs of ischemia in the chest leads, D1 andaVL in the electrocardiograms (ECGs). In al lcases, echocardiography (ECHO) showed mitral insufficiency and the dilation of the left ventricle and the mean ejection fraction was 29,3% (18-39%), and the mean shortening fraction was 12,6% (8-19%) in theECHOs. Diagnostic catheter angiography was performed for all patients and the diagnosis of ALCAPA was confirmed. All patients under went correction surgery with there implantation method. Four of the patients completely recovered after surgery. One patient died 5 days after the surgery. One patient is being followed up with medical treatment since there was no improvement in her cardiac functions after surgery.

MATERIALS and METHODS:

Six patients diagnosed with DCM at our clinic between January, 2005 and December, 2017 and detected with ALCAPA syndrome in their etiological assessment we re-evaluated retrospectively

INTRODUCTION:

Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) is a rare congenital cardiac anomaly that can be cured with surgical treatment. It accounts for 0.25 to 0.5% of all congenital heart diseases. ALCAPA is generally asymptomatic in the neonatal period. Dilated cardiomyopathy (DCM) and mitral valve insufficiency (MVI) are detected in patients with symptoms of heart failure. ALCAPA, which is a rare cause of DCM, early surgical treatment provides quite good prognosis in the first year of life. However, mortality is high in patientswho do not receive surgical treatment.